Targeted polymeric prodrugs containing multifunctional linkers

1. A compound of the Formula (I)

wherein:

R 1 is a polyalkylene oxide;

A is a capping group or

each D 1 is independently selected from the group consisting of targeting moieties, functional groups and leaving groups;

each D 2 is independently selected from the group consisting of biologically active moieties, functional groups and leaving groups;

each L 1 is an independently selected permanent linker selected from the group consisting of:

L 2 is a multifunctional linker is selected from the group consisting of:

wherein

R 2 is selected from the group consisting of hydrogen, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-19 branched alkyl, C 3 -8 cycloalkyl, C 1-6 substituted alkyl, C 2-6 substituted alkenyl, C 2-6 substituted alkynyl, C 3-8 substituted cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, C 1-6 heteroalkyl, substituted C 1-6 heteroalkyl, C 1-6 alkoxy, aryloxy, C 1-6 heteroalkoxy, heteroaryloxy, C 2-6 alkanoyl, arylcarbonyl, C 2-6 alkoxycarbonyl, aryloxycarbonyl, C 2-6 alkanoyloxy, arylcarbonyloxy, C 2-6 substituted alkanoyl, substituted arylcarbonyl, C 2-6 substituted alkanoyloxy, substituted aryloxycarbonyl, C 2-6 substituted alkanoyloxy and substituted arylcarbonyloxy;

each L 3 is an independently selected permanent linker or a releasable linker,

wherein the releasable linker is selected from the group consisting of:

-Val-Cit-,

-Gly-Phe-Leu-Gly-,

-Ala-Leu-Ala-Leu-

-Phe-Lys-,

-Val-Cit-C(═O)—CH 2 OCH 2 —C(═O)—,

-Val-Cit-C(═O)—CH 2 SCH 2 —C(═O)—, and

—NHCH(CH 3 )—C(═O)—NH(CH 2 ) 6 —C(CH 3 ) 2 —C(═O)—,

wherein

Y 11-19 are independently O, S or NR 48 ;

R 31-48 , R 50 , R 100 and A 51 are independently selected from the group consisting of hydrogen, C 1-6 alkyls, C 3-12 branched alkyls, C 3-8 cycloalkyls, C 1-6 substituted alkyls, C 3-8 substituted cyloalkyls, aryls, substituted aryls, aralkyls, C 1-6 heteroalkyls, substituted C 1-6 heteroalkyls, C 1-6 alkoxy, C 1-6 alkyloxycarbonyl, phenoxy and C 1-6 heteroalkoxy;

Ar is an aryl or heteroaryl moiety;

L 11-15 are independently selected bifunctional spacers;

Z and Z′ are independently selected from selected from the group consisting of moieties actively transported into a target cell, hydrophobic moieties, bifunctional linking moieties and combinations thereof;

(c11), (h11), (k11), (l11), (m11) and (n11) are one;

(a11), (e11), (g11), (j11), (o11) and (q11) are independently either zero or one; and

(b11), (x11), (x′12), (f11), (i11) and (p11) are independently zero or one; and

(a) and (b) are independently zero or one.

2. A compound of claim 1 , selected from the group consisting of:

3. The compound of claim 1 , wherein the biologically active moiety is selected from the group consisting of —NH 2 containing moieties, —OH containing moieties and —SH containing moieties.

4. The compound of claim 1 , wherein the biologically active moiety is selected from the group consisting of pharmaceutically active compounds, enzymes, proteins, oligonucleotides, antibodies, monoclonal antibodies, single chain antibodies and peptides.

5. The compound of claim 4 , wherein the pharmaceutically active compounds are selected from the group consisting of DNA topoisomerase inhibitors, microtubule inhibiting drugs, DNA damaging agents, antimetabolites, nucleoside analogs and anticancer drugs.

6. The compound of claim 1 , wherein the biologically active moiety is an oligonucleotide.

7. The compound of claim 6 , wherein the oligonucleotide is selected from the group consisting of antisense oligonucleotides, locked nucleic acids (LNA), short interfering RNA (siRNA), microRNA (miRNA), aptamers, peptide nucleic acid (PNA), and phosphorodiamidate morpholino oligonucleotides (PMO).

8. The compound of claim 6 , wherein the oligonucleotide is selected from the group consisting of antisens bcl-2 oligonucleotides, antisense HIF-1α oligonucleotides, and antisense Survivin oligonucleotides.

9. The compound of claim 1 , wherein the targeting agent is selected from the group consisting of monoclonal antibodies, single chain antibodies, cell adhesion peptides, cell penetrating peptides, receptor ligands, targeting carbohydrate molecules or lectins and oligonucleotide.

10. The compound of claim 1 , wherein the targeting agent is selected from the group consisting of RGD peptide, selectin, TAT, penetratin, (Arg) 9 and folic acid.

11. The compound of claim 1 , wherein the releasable linker is selected from the group consisting of benzyl elimination-based linkers, trialkyl lock-based linkers, bicine-based linkers, acid-labile linkers, lysosomally cleavable peptides and capthepsin B cleavable peptides.

12. The compound of claim 1 , wherein the polyalkylene oxide is selected from the group consisting of polyethylene glycol and polypropylene glycol.

13. The compound of claim 1 , wherein the polyalkylene oxide is selected from the group consisting of

—Y 21 —(CH 2 CH 2 O) n —CH 2 CH 2 Y 21 —,

—Y 21 —(CH 2 CH 2 O) n —CH 2 C(═Y 22 )—Y 21 —,

—Y 21 —C(═Y 22 )—(CH 2 ) a2 —Y 23 —(CH 2 CH 2 O) n —CH 2 CH 2 —Y 23 —(CH 2 ) a2 —C(═Y 22 )—Y 21 — and

—Y 21 —(CR 51 R 52 ) a2 —Y 23 —(CH 2 ) b2 —O—(CH 2 CH 2 O) n —(CH 2 ) b2 —Y 23 —(CR 51 R 52 ) a2 —Y 21 —,

wherein:

Y 21 and Y 23 are independently O, S, SO, SO 2 , NR 53 or a bond;

Y 22 is O, S, or NR 53 ;

R 51-53 are independently selected from the group for R 2 ;

(a2) and (b2) are independently zero or a positive integer; and

(n) is an integer from about 10 to about 2300.

14. The compound of claim 1 wherein the polyalkylene oxide is a polyethylene glycol of the formula, —O—(CH 2 CH 2 O)—

wherein (n) is an integer from about 10 to about 2,300.

15. The compound of claim 1 , wherein R 1 has an average molecular weight from about 2,000 to about 100,000 daltons.

16. The compound of claim 1 , wherein R 1 has an average molecular weight of from about 5,000 to about 60,000 daltons.

17. The compound of claim 1 , wherein R 1 has an average molecular weight from about 5,000 to about 25,000 daltons or from about 20,000 to about 45,000 daltons.

18. A compound of claim 1 , selected from the group consisting of:

wherein

mPEG has the formula: CH 3 —O(CH 2 CH 2 O) n —;

PEG has the formula —O(CH 2 CH 2 O) n —;

(n) is a positive integer from about 10 to about 2,300;

R 51 and R 52 are independently selected from the group consisting of hydrogen, C 1-6 alkyls, C 3-12 branched alkyls, C 3-8 cycloalkyls, C 1-6 substituted alkyls, C 3-8 substituted cyloalkyls, aryls, substituted aryls, aralkyls, C 1-6 heteroalkyls, substituted C 1-6 heteroalkyls, C 1-6 alkoxy, C 1-6 alkyloxycarbonyl, aryloxycarbonyl, phenoxy and C 1-6 heteroalkoxy;

D 1 is a targeting moiety, a functional group or a leaving group; and

D 2 is a biologically active moiety, a functional group or a leaving group.

19. A compound of claim 1 , selected from the group consisting of:

wherein

S-SCA is a single-chain antibody;

RGD is

LNA is locked nucleic acids;

Folic acid is a residue of

mPEG has the formula: CH 3 —O(CH 2 CH 2 O) n —;

PEG has the formula —O(CH 2 CH 2 O) n —; and

(n) is a positive integer from about 10 to about 2,300.